Skip to main content
OKUR
NASDAQ Life Sciences

OnKure Proposes 8% Equity Plan Increase and Removes Evergreen Limit Ahead of Annual Meeting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.88
Mkt Cap
$66.727M
52W Low
$1.7
52W High
$5.08
52W Position info
187% above low
Off High info
3.9% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

OKUR has more than doubled off its 52-week low of $1.7 on light trading volume (0.2× avg).

Summary

OnKure Therapeutics filed definitive additional proxy materials, proposing to increase its equity incentive plan by approximately 8% of outstanding shares and remove the annual evergreen limit, ahead of its June 3, 2026 annual meeting.


Key Events · Corporate Governance and Compliance · OKUR

  • Proposed Equity Plan Expansion

    Shareholders will vote on amending the 2024 Equity Incentive Plan to increase shares reserved for issuance by approximately 8% of outstanding shares.

  • Removal of Evergreen Limit

    The amendment also seeks to remove the annual limit of 2,407,100 shares from the plan's "evergreen" provision, allowing for automatic replenishment without a specific annual cap.

  • Annual Meeting Details

    The annual meeting is scheduled for June 3, 2026, where shareholders will also elect directors and ratify the independent auditor.


Analysis · OKUR · Life Sciences

This DEFA14A filing outlines proposals for OnKure Therapeutics' upcoming annual meeting, most notably a significant amendment to the 2024 Equity Incentive Plan. The proposed changes include increasing the shares reserved for issuance by approximately 8% of outstanding shares and removing the annual limit from the "evergreen" provision. This potential dilution is substantial, especially for a company that recently disclosed going concern doubts and initiated an ATM program. However, it is a common mechanism for retaining and incentivizing employees, which is critical for a company in its current stage, particularly following a recent large strategic investment by Access Industries. Shareholders should consider the long-term implications of this dilution for employee compensation.

At the time of this filing, OKUR was trading at $4.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.7M. The 52-week trading range was $1.70 to $5.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OKUR - Latest Insights

OKUR
Jun 04, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.30
Real-time Price: $4.08 info
Change: -$0.220 (-5%) info
Market Cap: $164.814M info
OKUR
May 05, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.52
Real-time Price: $4.08 info
Change: -$0.440 (-10%) info
Market Cap: $164.814M info
OKUR
May 05, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.38
Real-time Price: $4.08 info
Change: -$0.300 (-7%) info
Market Cap: $164.814M info
OKUR
May 05, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.38
Real-time Price: $4.08 info
Change: -$0.300 (-7%) info
Market Cap: $164.814M info
OKUR
Apr 21, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $4.88
Real-time Price: $4.08 info
Change: -$0.800 (-16%) info
Market Cap: $164.814M info